within Pharmacolibrary.Drugs.ATC.C;

model C10AX18
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.5833333333333333e-06,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0031,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0076,
    k12             = 0.096,
    k21             = 0.096
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10AX18</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Volanesorsen is an antisense oligonucleotide drug designed to inhibit the synthesis of apolipoprotein C-III (ApoC-III), a protein involved in the metabolism of triglyceride-rich lipoproteins. It is primarily used for the treatment of familial chylomicronemia syndrome (FCS) in adults, a rare genetic disorder characterized by extremely elevated triglyceride levels. Volanesorsen has received conditional approvals in the EU and other selected markets.</p><h4>Pharmacokinetics</h4><p>Reported pharmacokinetic parameters in healthy adult volunteers and patients with hypertriglyceridemia following subcutaneous administration.</p><h4>References</h4><ol><li><p>Tomlinson, B, et al., &amp; Lam, CWK (2020). Pharmacokinetics of current and emerging treatments for hypercholesterolemia. <i>Expert opinion on drug metabolism &amp; toxicology</i> 16(5) 371–385. DOI:<a href=\"https://doi.org/10.1080/17425255.2020.1749261\">10.1080/17425255.2020.1749261</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32223657/\">https://pubmed.ncbi.nlm.nih.gov/32223657</a></p></li><li><p>Post, N, et al., &amp; Wang, Y (2019). Metabolism and Disposition of Volanesorsen, a 2&#x27;-. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 47(10) 1164–1173. DOI:<a href=\"https://doi.org/10.1124/dmd.119.087395\">10.1124/dmd.119.087395</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31350288/\">https://pubmed.ncbi.nlm.nih.gov/31350288</a></p></li><li><p>Ray, KK, et al., &amp; Ruotolo, G (2025). Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies. <i>Journal of the American College of Cardiology</i> 85(19) 1803–1818. DOI:<a href=\"https://doi.org/10.1016/j.jacc.2025.03.005\">10.1016/j.jacc.2025.03.005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40158211/\">https://pubmed.ncbi.nlm.nih.gov/40158211</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10AX18;
